Department of Internal Medicine, VU University Medical Center, De Boelelaan 1117, Amsterdam, HV, 1081, The Netherlands.
Research and Expertise Center in Pharmacotherapy Education, Amsterdam, The Netherlands, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Br J Clin Pharmacol. 2021 Dec;87(12):4853-4860. doi: 10.1111/bcp.14885. Epub 2021 May 26.
The Junior Adverse Drug Event Manager (J-ADEM) team is a multifaceted intervention focusing on real-life education for medical students that has been shown to assist healthcare professionals in managing and reporting suspected adverse drug reactions (ADRs) to the Netherlands Pharmacovigilance Centre Lareb. The aim of this study was to quantify and describe the ADRs reported by the J-ADEM team and to determine the clinical potential of this approach. The J-ADEM team consisted of medical students tasked with managing and reporting ADRs in hospitalized patients. All ADRs screened and reported by J-ADEM team were recorded anonymously, and categorized and analysed descriptively. From August 2018 through January 2020, 209 patients on two wards in an academic hospital were screened for ADR events. The J-ADEM team reported 101 ADRs. Although most ADRs (67%) were first identified by healthcare professionals and then reported by the J-ADEM team, the team also reported an additional 33 not previously identified serious ADRs. In 10% of all reported ADRs, the J-ADEM team helped optimize ADR treatment. The ADR reports were largely well-documented (78%), and ADRs were classified as type A (66%), had a moderate or severe severity (85%) and were predominantly avoidable reactions (69%). This study shows that medical students are able to screen patients for ADRs, can identify previously undetected ADRs and can help optimize ADR management. They significantly increased (by 300%) the number of ADR reports submitted, showing that the J-ADEM team can make a valuable clinical contribution to hospital care.
初级药物不良事件经理 (J-ADEM) 团队是一项多方面的干预措施，专注于对医学生进行现实生活教育，已被证明有助于医疗保健专业人员向荷兰药物警戒中心 Lareb 报告疑似药物不良反应 (ADR)。本研究旨在定量和描述 J-ADEM 团队报告的 ADR，并确定该方法的临床潜力。J-ADEM 团队由负责管理和报告住院患者 ADR 的医学生组成。J-ADEM 团队筛选和报告的所有 ADR 均匿名记录，并进行分类和描述性分析。从 2018 年 8 月到 2020 年 1 月，在一家学术医院的两个病房对 209 名患者进行了 ADR 筛查。J-ADEM 团队报告了 101 例 ADR。尽管大多数 ADR（67%）是由医疗保健专业人员首先发现并由 J-ADEM 团队报告的，但团队还报告了另外 33 例先前未发现的严重 ADR。在所有报告的 ADR 中，有 10%的 ADR 得到了 J-ADEM 团队的优化治疗。ADR 报告记录大部分详实（78%），ADR 被分类为 A 型（66%），严重程度为中度或重度（85%），主要是可避免的反应（69%）。本研究表明，医学生能够对患者进行 ADR 筛查，能够识别以前未检测到的 ADR，并能够帮助优化 ADR 管理。他们显著增加了（增加了 300%）提交的 ADR 报告数量，表明 J-ADEM 团队可以为医院护理做出有价值的临床贡献。
